about
Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?Correspondence between neurophysiological and clinical measurements of chemotherapy-induced peripheral neuropathy: secondary analysis of data from the CI-PeriNomS study.The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools.Chemotherapy-induced peripheral neurotoxicity in the era of pharmacogenomics.Management of side effects in the personalized medicine era: chemotherapy-induced peripheral neuropathy.Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study.Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.Neurophysiological examination of dorsal sural nerve.Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: results from a prospective multicenter study.Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective.Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer.Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery.Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity.Evaluation of the Profile and Mechanism of Neurotoxicity of Water-Soluble [Cu(P)4]PF6 and [Au(P)4]PF6 (P = thp or PTA) Anticancer Complexes.Erratum to: Distal pain and carpal tunnel syndrome diagnosis among cashiers: a longitudinal study.Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients.Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study.Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients.Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures StRisk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.Severe, reversible nelarabine-induced neuropathy and myelopathy.Neuropathic pain and chemotherapy-induced peripheral neurotoxicity: the issue.Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.High-dose intravenous immunoglobulins reduce nerve macrophage infiltration and the severity of bortezomib-induced peripheral neurotoxicity in ratsLong-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up studyIncidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancerChemotherapy-Induced NeuropathyGhrelin agonist HM01 attenuates chemotherapy-induced neurotoxicity in rodent modelsNeurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathyChemotherapy-induced peripheral neurotoxicity – outcome measures: the issueVinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatmentBortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatmentOverview and critical revision of clinical assessment tools in chemotherapy-induced peripheral neurotoxicityChemotherapy-induced peripheral neurotoxicity: A multifaceted, still unsolved issue
P50
Q28083308-E840EEB1-F8E0-4E66-B678-4A734D58A62FQ30818191-E846177C-708A-4CA7-ACD0-BA39C61BA283Q36551631-8DA9FD0F-AA7C-4E6E-B9AE-85CC4F7B135BQ37404101-0908CA54-695C-44D6-B5F3-902E2C4E810EQ37666056-B60CE41F-94EC-4FFC-9C4C-715592536F09Q37896345-ECF79A1F-51BF-4703-A372-55BF59B33D16Q38242607-D83C8F2D-07F5-40BF-9A48-F0AAEFD0D8E1Q38716238-E693327A-A33F-4936-B0EA-3FA4A0F30CA4Q39419874-8B9EC95B-63D9-44BE-8E69-BF0FC52C88D9Q41095276-D31D78BE-656D-4996-B42F-BC02D46D0281Q43801654-29F3C17F-6B7F-4213-9CF2-1A0B49EFC4A9Q44304377-CABE0420-69D0-44BA-B652-6F003855D745Q44377966-F12A187F-C355-4BE7-B7EC-ABADC311DED9Q45091068-99AD905F-79AC-4023-A7CD-1C48C17515E4Q46235962-425C1B40-41AA-45F2-8B8C-12BB92AC0F4FQ47266458-180168BD-50E2-483A-AEE0-A61FF8347EF8Q47293439-4099332F-8D3A-4FF2-B0BE-7C2E5B125BD4Q47558946-AF06C0DF-77F9-47E0-B7D8-C8C4C78FCE00Q47712025-E94272C4-8261-4521-B9D9-E13D64B7959EQ48332162-E7B67D6A-CA72-40DE-925E-1D8E1C31B779Q50797877-C8D36978-EC90-450D-8F78-AB7B9537A276Q50887433-E5316394-541A-4173-9217-ACA9EFCB9237Q50922149-5691796B-5D7E-442D-9B4E-EDD2221CFC5BQ51000217-6420B94B-70D7-4D61-B3C5-5D00A30C89E9Q52591943-244742BA-0BF5-4AE3-9414-58185811E961Q53824674-5C0B7344-B39F-42AB-8DE5-DE65B0DDE904Q53971707-54DAA4BB-1963-44F4-BA05-97E04E9633D5Q54283638-83B59862-8784-4C13-868C-541211FBBFCAQ55491433-BC68FAD0-9E72-4AA4-8F33-10E985853C46Q58731210-9FBFD6AA-59D8-4D17-A6BB-89AB04EF7E5AQ58874339-1715F85F-FF2E-4A95-9B5A-779E002CD4C1Q58874370-D83472B9-49C8-4B3E-9853-777DDFEFDB46Q58874394-6CF9BC1D-C56E-4708-A1DB-4B0DCDD0C8A0Q61439842-3090F7B8-2D51-4BA3-89BE-1D1D3E53A2E5Q61439843-778EF4CF-D4E9-457D-9E6A-A8BDCA358DEDQ61439849-C25020ED-7057-4EFC-9AA8-C3D154BBCC72Q90919271-182D1FF7-68F0-4CE8-BCFE-5C585B1BE656Q90919275-14BD338F-1119-47B4-9AFD-B9052397516CQ90919279-53CBB860-2B48-41B1-B913-F69E3520611FQ90919283-D8F5C32B-AF4A-442E-BBF5-737A4EA5D621
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Paola Alberti
@ast
Paola Alberti
@en
Paola Alberti
@es
Paola Alberti
@nl
Paola Alberti
@sl
type
label
Paola Alberti
@ast
Paola Alberti
@en
Paola Alberti
@es
Paola Alberti
@nl
Paola Alberti
@sl
prefLabel
Paola Alberti
@ast
Paola Alberti
@en
Paola Alberti
@es
Paola Alberti
@nl
Paola Alberti
@sl
P106
P1153
7103068082
P1960
UCoILMwAAAAJ
P2038
Paola_Alberti
P21
P31
P3835
paola-alberti
P496
0000-0001-6106-6183